Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by iA Global Asset Management Inc.

iA Global Asset Management Inc. trimmed its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 11.7% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,648 shares of the biopharmaceutical company's stock after selling 1,538 shares during the period. iA Global Asset Management Inc.'s holdings in Regeneron Pharmaceuticals were worth $8,297,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. FSA Wealth Management LLC purchased a new position in Regeneron Pharmaceuticals during the 3rd quarter valued at about $26,000. OFI Invest Asset Management acquired a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $28,000. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 62.5% during the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company's stock worth $28,000 after purchasing an additional 15 shares in the last quarter. Avalon Trust Co purchased a new position in shares of Regeneron Pharmaceuticals in the fourth quarter valued at approximately $36,000. Finally, Private Wealth Management Group LLC grew its holdings in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company's stock valued at $38,000 after purchasing an additional 39 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Performance

Regeneron Pharmaceuticals stock traded down $26.86 during midday trading on Tuesday, hitting $634.14. 852,346 shares of the company's stock were exchanged, compared to its average volume of 635,607. The stock has a market cap of $69.33 billion, a price-to-earnings ratio of 16.57, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a 12-month low of $642.00 and a 12-month high of $1,211.20. The firm's 50 day simple moving average is $688.31 and its 200 day simple moving average is $809.71.

Remove Ads

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, beating the consensus estimate of $11.21 by $0.86. The firm had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business's revenue for the quarter was up 10.3% compared to the same quarter last year. During the same quarter last year, the business earned $11.86 earnings per share. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Investors of record on Thursday, February 20th were paid a $0.88 dividend. The ex-dividend date was Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.56%. Regeneron Pharmaceuticals's payout ratio is 2.30%.

Wall Street Analyst Weigh In

REGN has been the topic of a number of research reports. UBS Group cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "neutral" rating and decreased their price target for the company from $1,130.00 to $738.00 in a research report on Thursday, January 16th. Citigroup decreased their target price on Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a report on Tuesday, January 28th. Wells Fargo & Company lowered their target price on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research note on Friday, January 10th. Leerink Partnrs raised Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, February 5th. Finally, Bank of America reissued an "underperform" rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.